MD, PhD, FASN, FAST, Professor Haraldsson has served for 15 years as Chair of nephrology at the University of Gothenburg, Sweden, and as senior consultant at the nephrology clinic at Sahlgrenska University hospital, Gothenburg. Most recently, he initiated and lead high-profile global drug development projects in nephrology, transplantation, and rheumatology at Novartis, Switzerland. Read more about Börje Haraldsson here.
MBA, PhD in Clinical Nephrology focused Pharmacokinetics. Pål Falck has a broad background within the life science sector including Nordic Medical Director in Oncology & Infections at AstraZeneca, Medical Advisor and Business Development at Pfizer Norway, Healthcare Equity Research Analyst at Arctic Securities in Norway.
PhD in Clinical Immunology Karolinska Institute, PMP. Susanna Dahlgren has a long experience in drug development from various positions in the pharmaceutical industry including Astrazeneca, ALK, Polypeptide, Aqilion and SDS Life Science, focusing on project leadership from early drug discovery to clinical development, medical affairs and scientific marketing. Read more about Susanna Dahlgren here.
Hanjing Xie, MD, PhD in Clinical Pharmacology, is an Associate Professor of Oncology at Karolinska Institutet and is triple board-certified in clinical oncology, internal medicine, and hematology. With more than 30 years of experience in clinical practice, cancer research, and drug development, she brings deep scientific and clinical expertise together with a strong record of executive leadership. Before transitioning to the pharmaceutical industry, Dr. Xie served as a senior consultant (Docent Överläkare) at Karolinska University Hospital. She began her industry career at Bayer and later joined Oncopeptides, before taking on senior leadership roles in global pharmaceutical companies and emerging biotechnology firms. Her executive experience includes serving as Chief Medical Officer at Idogen AB, Kancera AB, NeoGap Therapeutics AB, Amal Therapeutics SA, and Boehringer Ingelheim’s Oncology Research Department, formerly CIIM.
MSc Chemistry, Uppsala University, Med. Lic. Karolinska Institute. Ann-Kristin Spiik has a broad experience in drug development and project management with focus on CMC and related activities such as regulatory submissions. She has worked in different phases of development and in companies ranging from early academic spin-offs to larger pharmaceutical companies.
Christer Lundell-Ek has extensive clinical experience as a registered nurse in, e.g., oncology and hemodialysis. He has 30 years of experience in clinical operation activities, including quality and supply from large pharma companies as well as from small biotech and medical device companies.
MSc Pharm from Uppsala University. Åsa Holmgren has over 30 years of experience in Global Strategic Regulatory Affairs and Drug Development in pharmaceutical companies. She has held leadership positions and led regulatory strategies at Medivir AB, Orexo AB, AstraZeneca R&D, Pharmacia & Upjohn R&D, and Roche AB. Read more about Åsa Holmgren here.